See more : Arabian Shield Cooperative Insurance Company (8070.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Cue Biopharma, Inc. (CUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cue Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- V V Food & Beverage Co.,Ltd (600300.SS) Income Statement Analysis – Financial Results
- BP p.l.c. (BPAQF) Income Statement Analysis – Financial Results
- Asia Dragon Trust plc (DGN.L) Income Statement Analysis – Financial Results
- VELTRA Corporation (7048.T) Income Statement Analysis – Financial Results
- C2 Blockchain, Inc. (CBLO) Income Statement Analysis – Financial Results
Cue Biopharma, Inc. (CUE)
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.49M | 1.25M | 14.94M | 3.15M | 3.46M | 1.14M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 38.10M | 1.81M | -1.78M | 33.55M | 27.49M | 28.54M | 419.57K | 202.09K | 44.82K |
| Gross Profit | -32.61M | -560.83K | 16.72M | -30.39M | -24.03M | -27.40M | -419.57K | -202.09K | -44.82K |
| Gross Profit Ratio | -593.93% | -45.04% | 111.90% | -963.48% | -694.90% | -2,398.16% | 0.00% | 0.00% | 0.00% |
| Research & Development | 40.80M | 38.58M | 41.35M | 33.55M | 27.49M | 28.54M | 18.90M | 5.69M | 1.50M |
| General & Administrative | 16.68M | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M | 4.33M | 1.97M | 425.08K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.68M | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M | 4.33M | 1.97M | 425.08K |
| Other Expenses | -37.94M | 0.00 | 0.00 | 0.00 | 64.00K | 165.34K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.54M | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M | 23.23M | 7.66M | 1.93M |
| Cost & Expenses | 57.64M | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M | 23.23M | 7.66M | 1.93M |
| Interest Income | 2.66M | 928.24K | 45.90K | 463.91K | 419.00K | 376.01K | 35.00 | 52.00 | 0.00 |
| Interest Expense | 1.25M | 713.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.44M | 1.81M | -1.78M | 1.06M | 5.35M | 760.01K | 419.57K | 202.09K | 44.82K |
| EBITDA | -46.05M | -50.49M | -45.44M | -43.99M | -35.96M | -37.94M | -22.81M | -7.46M | -1.88M |
| EBITDA Ratio | -838.83% | -4,076.94% | -292.56% | -1,394.44% | -1,063.30% | -3,320.19% | 0.00% | 0.00% | 0.00% |
| Operating Income | -52.15M | -53.22M | -43.71M | -45.04M | -36.77M | -38.70M | -23.23M | -7.66M | -1.93M |
| Operating Income Ratio | -949.89% | -4,274.31% | -292.56% | -1,427.96% | -1,063.30% | -3,386.71% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 215.00K | 45.90K | 463.91K | 482.79K | 541.35K | 35.00 | 52.00 | 0.00 |
| Income Before Tax | -50.73M | -53.01M | -43.67M | -44.58M | -36.29M | -38.16M | -23.23M | -7.66M | -1.93M |
| Income Before Tax Ratio | -924.10% | -4,257.09% | -292.25% | -1,413.26% | -1,049.33% | -3,339.33% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -214.43K | 495.00K | 206.25K | 412.00K | 825.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -50.73M | -52.80M | -44.16M | -44.78M | -36.70M | -38.98M | -23.23M | -7.66M | -1.93M |
| Net Income Ratio | -924.10% | -4,239.87% | -295.56% | -1,419.79% | -1,061.25% | -3,411.53% | 0.00% | 0.00% | 0.00% |
| EPS | -1.11 | -1.48 | -1.41 | -1.56 | -1.66 | -1.94 | -1.13 | -0.37 | -0.09 |
| EPS Diluted | -1.11 | -1.48 | -1.41 | -1.56 | -1.66 | -1.94 | -1.13 | -0.37 | -0.09 |
| Weighted Avg Shares Out | 45.75M | 35.65M | 31.29M | 28.69M | 22.04M | 20.13M | 20.64M | 20.64M | 20.64M |
| Weighted Avg Shares Out (Dil) | 45.75M | 35.65M | 31.29M | 28.69M | 22.04M | 20.13M | 20.64M | 20.64M | 20.64M |
HHS invests $480 million in Cue Health to boost manufacturing of rapid coronavirus test
Fintech Machine Learning Leader Attunely Secures $9M in Funding
Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds
Wall Street Breakfast: The Week Ahead
Stocks To Watch: Apple, Snowflake, Pfizer And Moderna In Focus
How To Predict Sales Growth
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call Transcript
Wall Street Breakfast: The Week Ahead
Stocks To Watch: Nvidia, Intel And Zoom Look To Dazzle
DeFi fintech studio Framework Labs raises $8M seed round » CryptoNinjas
Source: https://incomestatements.info
Category: Stock Reports